HomeCompareAVCTF vs ORCC

AVCTF vs ORCC: Dividend Comparison 2026

AVCTF yields 230.65% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVCTF wins by $279.19M in total portfolio value
10 years
AVCTF
AVCTF
● Live price
230.65%
Share price
$0.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$279.22M
Annual income
$150,694,330.53
Full AVCTF calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — AVCTF vs ORCC

📍 AVCTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVCTFORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVCTF + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AVCTF pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVCTF
Annual income on $10K today (after 15% tax)
$19,605.58/yr
After 10yr DRIP, annual income (after tax)
$128,090,180.95/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, AVCTF beats the other by $128,090,180.07/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVCTF + ORCC for your $10,000?

AVCTF: 50%ORCC: 50%
100% ORCC50/50100% AVCTF
Portfolio after 10yr
$139.62M
Annual income
$75,347,165.78/yr
Blended yield
53.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

AVCTF
Analyst Ratings
1
Sell
Consensus: Sell
Altman Z
-7.0
Piotroski
3/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVCTF buys
0
ORCC buys
0
No recent congressional trades found for AVCTF or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVCTFORCC
Forward yield230.65%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$279.22M$21.4K
Annual income after 10y$150,694,330.53$1.04
Total dividends collected$265.09M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusSellBuy

Year-by-year: AVCTF vs ORCC ($10,000, DRIP)

YearAVCTF PortfolioAVCTF Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$33,765$23,065.39$11,190$489.61+$22.6KAVCTF
2$108,915$72,786.16$12,229$256.01+$96.7KAVCTF
3$335,962$219,422.65$13,216$130.74+$322.7KAVCTF
4$992,036$632,556.65$14,207$66.02+$977.8KAVCTF
5$2,807,112$1,745,633.43$15,234$33.17+$2.79MAVCTF
6$7,619,990$4,616,380.77$16,317$16.62+$7.60MAVCTF
7$19,864,891$11,711,501.13$17,468$8.32+$19.85MAVCTF
8$49,789,295$28,533,861.41$18,695$4.16+$49.77MAVCTF
9$120,113,025$66,838,479.41$20,006$2.08+$120.09MAVCTF
10$279,215,267$150,694,330.53$21,407$1.04+$279.19MAVCTF

AVCTF vs ORCC: Complete Analysis 2026

AVCTFStock

Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Full AVCTF Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this AVCTF vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVCTF vs SCHDAVCTF vs JEPIAVCTF vs OAVCTF vs KOAVCTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.